Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Deferred Revenue: 2013-2024

Historic Current Deferred Revenue for Ocular Therapeutix (OCUL) over the last 7 years, with Dec 2024 value amounting to $14.1 million.

  • Ocular Therapeutix's Current Deferred Revenue fell 1.34% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year decrease of 1.34%. This contributed to the annual value of $14.1 million for FY2024, which is 1.82% down from last year.
  • As of FY2024, Ocular Therapeutix's Current Deferred Revenue stood at $14.1 million, which was down 1.82% from $14.4 million recorded in FY2023.
  • Ocular Therapeutix's Current Deferred Revenue's 5-year high stood at $14.4 million during FY2023, with a 5-year trough of $13.0 million in FY2021.
  • In the last 3 years, Ocular Therapeutix's Current Deferred Revenue had a median value of $14.1 million in 2024 and averaged $14.2 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first increased by 7.41% in 2022, then fell by 1.82% in 2024.
  • Yearly analysis of 4 years shows Ocular Therapeutix's Current Deferred Revenue stood at $13.0 million in 2021, then climbed by 7.41% to $14.0 million in 2022, then grew by 3.06% to $14.4 million in 2023, then fell by 1.82% to $14.1 million in 2024.